Table 4. | Characteristics of studies included in systematic review, age, gender ratio, pathology and local and systemic agents used in each clinical trial |
| Study | Mean age (years) | Gender ratio | Pathology | Systemic agents | Local agents |
|---|---|---|---|---|---|
| Peisker et al. [3] | 32 (SD 22.5) |
14 males; 1 female |
H.A = 11; H.B = 4 |
Tranexamic acid; recombinant and plasma derived replacement therapy; desmopressin | Collagen vlies; oxycellulose; fibrin glue; sutures; compressive splints |
| Cocero et al. [5] | 6 - 78 |
83 males; 37 females |
H.A = 47; vWD = 53; H.B = 11; F V/XI = 9 |
Tranexamic acid; ugurol; desmopressin; plasma derived/recombinant replacement therapy | Fibrin glue; plasma rich growth factor |
| Kazancıoğlu et al. [12] | 20.3 (SD 11.4) | 27 males | H. A = 27 | Tranexamic acid; FVIII or FIX; rFVIIa (when inhibitors) | Ankaferd blood stopper; direct packing with gauze |
H.A = haemophilia A; H.B = haemophilia B; vWD = von Willebrand disease; F V/XI = factor V/XI deficiency; FVIII = factor VIII deficiency; FIX = factor IX deficiency; rFVIIa = recombinant activated factor VII; SD = standard deviation. |
.png)
.png)
.png)
.png)